Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib, Doxorubicin, and Strontium-89 in Prostate Cancer
NCT00080782Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2002
- Primary completion
- Apr 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of celecoxib oral solution in prostate cancer (PCa) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Time to prostate-specific antigen progression at 16 weeks. Started Feb 2002; status: terminated.
02
Drugs
celecoxib oral solution
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00080782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00080782.